Targin 20mg/10mg prolonged release tablets

*
Pharmacy Only: Prescription
qrcode image

Scan the QR code or enter an email to access and share this medicine:

Updated on 28 February 2025

File name

Proposed_IE_PIL_Targin_Prolonged Release Tablets_5_2.5 mg, 10_5 mg, 20_10 mg, 40_20 mg_clean.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

2.         What you need to know before you take Targin

Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) or the biliary tract system. 

Other medicines and Targin

·      muscle relaxants;

·      medicines to treat Parkinson’s disease.

4.      Possible side effects

Not known (frequency cannot be estimated from the available data)

  •  a problem affecting a valve in the intestines that may cause severe upper abdominal pain (sphincter of Oddi dysfunction)

6.        Contents of the pack and other information

What Targin looks like and contents of the pack

These tablets are available in blister packs of 10, 14, 20, 28, 30, 50, 56, 60, 98 and 100 or in a hospital pack of 100 (10 x 10) or in a bottle with child-resistant closure containing 100 tablets.

This leaflet was last revised in July 2024.

Updated on 28 February 2025

File name

ie-spc-targin-20 mg-10 mg-clean.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2.      QUALITATIVE AND QUANTITATIVE COMPOSITION

Each prolonged‑release tablet contains 5 mg of oxycodone hydrochloride equivalent to 4.5 mg oxycodone and 2.5 mg naloxone hydrochloride as 2.73 mg of naloxone hydrochloride dihydrate equivalent to 2.25 mg naloxone.

Excipient with known effect: Each prolonged‑release tablet contains 71.8 mg lactose monohydrate

For the full list of excipients, see section 6.1.

4.      CLINICAL PARTICULARS

Below point has been added in Section 4.4

4.4    Special warnings and precautions for use

Hepatobiliary disorders

Oxycodone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone / naloxone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract. 

Below point has been added in Section 4.5

4.5    Interaction with other medicinal products and other forms of interaction

Concomitant administration of oxycodone with anticholinergics or medications with anticholinergic activity (e.g. tri-cyclic antidepressants, antihistamines, anti-psychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects. 

10.    DATE OF REVISION OF THE TEXT

Updated on 09 May 2024

File name

PIL Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean - Sept 23.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 09 May 2024

File name

Targin Prolonged Release Tablets-20-10mg-clean - Sept 23.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 07 June 2023

File name

Patient Leaflet-PIL English Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean.pdf

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents

Updated on 07 June 2023

File name

Targin Prolonged Release Tablets-SmPC-20-10mg-clean.pdf

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 06 April 2023

File name

Targin Prolonged Release Tablets-20-10mg-clean.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

IE MAH Address Change

Updated on 06 April 2023

File name

Patient Leaflet-PIL English Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean.pdf

Reasons for updating

  • New PIL for new product

Free text change information supplied by the pharmaceutical company

IE MAH Address Change

Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories

mundi_logo